Published in Cancer Res on October 01, 1983
Methylthioadenosine (MTA) inhibits melanoma cell proliferation and in vivo tumor growth. BMC Cancer (2010) 0.98
Methylthioadenosine reprograms macrophage activation through adenosine receptor stimulation. PLoS One (2014) 0.77
Heterogeneity of tumor cells from a single mouse mammary tumor. Cancer Res (1978) 2.86
Tight-binding inhibitors--IV. Inhibition of adenosine deaminases by various inhibitors. Biochem Pharmacol (1977) 2.13
N,N-dimethylformamide-induced alteration of cell culture characteristics and loss of tumorigenicity in cultured human colon carcinoma cells. Cancer Res (1979) 2.05
Purine Metabolism in Tetrahymena and Its Relation to Malignant Cells in Mice. Science (1949) 1.83
Increased expression of the interleukin-11 receptor and evidence of STAT3 activation in prostate carcinoma. Am J Pathol (2001) 1.69
Guanylate kinases from human erythrocytes, hog brain, and rat liver. Methods Enzymol (1978) 1.60
Heterogeneity of cancer cells from a single human colon carcinoma. Am J Med (1981) 1.56
Heterogeneity in drug sensitivity among tumor cell subpopulations of a single mammary tumor. Cancer Res (1978) 1.48
Tumor heterogeneity and drug resistance. J Clin Oncol (1986) 1.47
Three-dimensional structure of human erythrocytic purine nucleoside phosphorylase at 3.2 A resolution. J Biol Chem (1990) 1.46
Squamous neoplasms of the stomach. Am J Roentgenol Radium Ther Nucl Med (1967) 1.36
Adenosine deaminase from human erythrocytes: purification and effects of adenosine analogs. Biochem Pharmacol (1975) 1.33
Purine nucleoside phosphorylase from human erythrocytes. IV. Crystallization and some properties. J Biol Chem (1969) 1.31
Tight-binding inhibitors-II. Non-steady state nature of inhibition of milk xanthine oxidase by allopurinol and alloxanthine and of human erythrocytic adenosine deaminase by coformycin. Biochem Pharmacol (1975) 1.27
Purine nucleoside phosphorylase. Microheterogeneity and comparison of kinetic behavior of the enzyme from several tissues and species. Biochemistry (1975) 1.25
Purine nucleoside phosphorylase from human erythroyctes. II. Kinetic analysis and substrate-binding studies. J Biol Chem (1968) 1.22
The clinical pharmacology of 5-trifluoromethyl-2'-deoxyuridine. Cancer Res (1972) 1.19
Purine nucleoside phosphorylase from human erythrocytes. I. Purification and properties. J Biol Chem (1968) 1.19
Human erythrocytic purine nucleoside phosphorylase: reaction with sugar-modified nucleoside substrates. Biochemistry (1980) 1.17
Nucleoside diphosphokinase from human erythrocytes. Methods Enzymol (1978) 1.17
Clinical and pharmacological implications of cancer cell differentiation and heterogeneity. Biochem Pharmacol (1979) 1.15
Polar solvents: a novel class of antineoplastic agents. J Clin Oncol (1984) 1.15
Potent inhibition of muscle 5'-AMP deaminase by the nucleoside antibiotics coformycin and deoxycoformycin. Biochem Pharmacol (1977) 1.13
Incorporation of analog purine nucleosides into the formed elements of human blood: erythrocytes, platelets, and lymphocytes. Ann N Y Acad Sci (1975) 1.13
Evaluation of a novel bis-naphthalimide anticancer agent, DMP 840, against human xenografts derived from adult, juvenile, and pediatric cancers. Cancer Chemother Pharmacol (1994) 1.08
Intraneoplastic diversity. Biochim Biophys Acta (1982) 1.06
Purine nucleoside phosphorylase. 3. Reversal of purine base specificity by site-directed mutagenesis. Biochemistry (1997) 1.05
Purine nucleoside metabolism in the erythrocytes of patients with adenosine deaminase deficiency and severe combined immunodeficiency. J Clin Invest (1976) 1.03
Erythrocytic nucleoside diphosphokinase. II. Isolation and kinetics. J Biol Chem (1966) 1.03
Inhibitors of purine nucleoside phosphorylase, C(8) and C(5') substitutions. Biochem Pharmacol (1982) 1.03
Preclinical antitumor activity of 6-hydroxymethylacylfulvene, a semisynthetic derivative of the mushroom toxin illudin S. Cancer Res (1997) 1.02
Correlation of umbilical cord blood haematopoietic stem and progenitor cell levels with birth weight: implications for a prenatal influence on cancer risk. Br J Cancer (2008) 1.02
Purine nucleoside phosphorylase from human erythrocytes. 3. Inhibition by the inosine analog formycin B of the isolated enzyme and of nucleoside metabolism in intact erythrocytes and sarcoma 180 cells. Mol Pharmacol (1968) 1.02
Human tumor cell heterogeneity and metastasis. J Clin Oncol (1983) 1.01
Experience with Hemophilus influenzae pneumonia. Radiology (1966) 1.00
Substrate specificities of 5'-deoxy-5'-methylthioadenosine phosphorylase from Trypanosoma brucei brucei and mammalian cells. Mol Biochem Parasitol (1988) 0.98
Synthesis and biological evaluation of 2-styrylquinazolin-4(3H)-ones, a new class of antimitotic anticancer agents which inhibit tubulin polymerization. J Med Chem (1990) 0.97
[Mouse teratocarcinoma: isolation and characterization of two muscle cell lines (author's transl)]. Ann Microbiol (Paris) (1976) 0.97
Adenosine deaminase from human erythrocytes. Methods Enzymol (1978) 0.97
5'-Methylthioadenosine phosphorylase-L. Substrate activity of 5'-deoxyadenosine with the enzyme from Sarcoma 180 cells. Biochem Pharmacol (1981) 0.96
Expression of methylthioadenosine phosphorylase cDNA in p16-, MTAP- malignant cells: restoration of methylthioadenosine phosphorylase-dependent salvage pathways and alterations of sensitivity to inhibitors of purine de novo synthesis. Mol Pharmacol (1997) 0.95
Forskolin: a potential antimetastatic agent. Int J Cancer (1983) 0.95
Effects of modulation of basic fibroblast growth factor on tumor growth in vivo. J Natl Cancer Inst (1993) 0.95
Purine metabolism in primitive erythrocytes. Comp Biochem Physiol B (1973) 0.95
Basic fibroblast growth factor-like activity and receptors are expressed in a human glioma cell line. Cancer Res (1990) 0.94
Erythrocytic nucleoside diphosphokinase. 3. Studies with free and phosphorylated enzyme and evidence for an essential thiol group. J Biol Chem (1966) 0.94
Adaptation of Sinclair swine melanoma cells to long-term growth in vitro. Cancer Res (1979) 0.94
Purine nucleoside phosphorylase from human erythrocytes. Methods Enzymol (1978) 0.94
Activity of a novel 4-quinolinecarboxylic acid, NSC 368390 [6-fluoro-2-(2'-fluoro-1,1'-biphenyl-4-yl)-3-methyl-4-quinolinecarb oxylic acid sodium salt], against experimental tumors. Cancer Res (1985) 0.93
Nucleotide profiles of the formed elements of human blood determined by high-pressure liquid chromatography. Blood (1973) 0.93
N,N-Dimethylformamide-induced morphological differentiation and reduction of tumorigenicity in cultured mouse rhabdomyosarcoma cells. Cancer Res (1977) 0.93
Expression of multiple angiogenic cytokines in cultured normal human prostate epithelial cells: predominance of vascular endothelial growth factor. Int J Cancer (1999) 0.91
Plasminogen activator and inhibitor activity in human glioma cells and modulation by sodium butyrate. Cancer Res (1988) 0.91
Purine nucleoside phosphorylase from human erythrocytes: physiocochemical properties of the crystalline enzyme. Biochemistry (1978) 0.90
Chemotherapy of cell-line-derived human colon carcinomas in mice immunosuppressed with antithymocyte serum. Cancer (1977) 0.89
Establishment and characterization of two human pancreatic cancer cell lines tumorigenic in athymic mice. Cancer Res (1982) 0.89
An hypothesis on the mechanism of action of 6-thioguanine. Biochem Pharmacol (1967) 0.89
Sodium butyrate-induced alteration of growth properties and glycogen levels in cultured human colon carcinoma cells. Histochem J (1984) 0.89
Structure-activity relationship of quinoline carboxylic acids. A new class of inhibitors of dihydroorotate dehydrogenase. Biochem Pharmacol (1990) 0.89
Changes in nucleoside transport of HL-60 human promyelocytic cells during N,N-dimethylformamide induced differentiation. Cancer Res (1986) 0.88
Characterization of a defect in the pathway for converting 5'-deoxy-5'-methylthioadenosine to methionine in a subline of a cultured heterogeneous human colon carcinoma. J Biol Chem (1984) 0.88
Reaction of 5'-deoxyadenosine and related analogs with the 5'-methylthioadenosine cleaving enzyme of sarcoma 180 cells, a possible chemotherapeutic target enzyme. Biochem Pharmacol (1979) 0.87
Incorporation of nucleosides into the nucleotide pools of human erythrocytes. Adenosine and its analogs. Biochemistry (1973) 0.87
Polar solvent-induced changes in membrane lipid lateral diffusion in human colon cancer cells. Cancer Res (1985) 0.86
Design of purine nucleoside phosphorylase inhibitors. Fed Proc (1986) 0.86
Maturation-induction of tumor cells using a human colon carcinoma model. Cancer (1980) 0.86
Tight binding inhibitors--VIII. Studies of the interactions of 2'-deoxycoformycin and transport inhibitors with the erythrocytic nucleoside transport system. Biochem Pharmacol (1980) 0.86
Interleukin-11 receptor expression in primary ovarian carcinomas. Gynecol Oncol (2001) 0.86
Alteration of the survival response of two human colon carcinoma subpopulations to x-irradiation by N,N-dimethylformamide. Cancer Res (1982) 0.86
Enhancement of the responses of human colon adenocarcinoma cells to X-irradiation and cis-platinum by N-methylformamide (NMF). Int J Radiat Oncol Biol Phys (1985) 0.86
Succinic thiokinase. V. Preparation of labeled substrates, their bindings to the enzyme, and isotope exchange studies. J Biol Chem (1967) 0.85
Characterization of two metastatic subpopulations originating from a single human colon carcinoma. Cancer Res (1983) 0.85
Enhancement by N-methylformamide of the effect of ionizing radiation on a human colon tumor xenografted in nude mice. Cancer Res (1984) 0.85
Role of glutathione depletion in the mechanism of action of N-methylformamide and N,N-dimethylformamide in a cultured human colon carcinoma cell line. Cancer Res (1986) 0.85
Disaggregation studies of xenograft solid tumors grown from pure or admixed clonal subpopulations from a heterogeneous human colon adenocarcinoma. Invasion Metastasis (1985) 0.84
Basic fibroblast growth factor: a potential autocrine regulator of human glioma cell growth. J Neurosci Res (1990) 0.83
Identification and isolation on a large scale of guanylate kinase from human erythrocytes. Effects of monophosphate nucleotides of purine analogs. Biochem Pharmacol (1971) 0.83
Erythrocytic nucleoside diphosphokinase. V. Some properties and behavior of the pI 7.3 isozyme. J Biol Chem (1971) 0.83
The interaction of the nucleoside analogues, formycins A and B, with xanthine oxidase and hepatic aldehyde oxidase. Mol Pharmacol (1970) 0.83
Inhibitors of purine nucleoside phosphorylase: effects of 9-deazapurine ribonucleosides and synthesis of 5'-deoxy-5'-iodo-9-deazainosine. Cancer Res (1986) 0.82
Purine nucleoside phosphorylase from human erythrocytes. V. Content and behavior of sulfhydryl groups. J Biol Chem (1971) 0.82
Succinic thiokinase. IV. Improved method of purification, arsenolysis of guanosine triphosphate, succinate-dependent guanosine triphos- phatase activity, and some other properties of the enzyme. J Biol Chem (1967) 0.82
Adenosine metabolism in human whole blood. Effects of nucleoside transport inhibitors and phosphate concentration. Biochem Pharmacol (1988) 0.82
Adenosine triphosphate-guanosine 5'-phosphate phosphotransferase. IV. Isozymes in human erythrocytes and Sarcoma 180 ascites cells. Mol Pharmacol (1972) 0.82
Demonstration of the heterogeneity of nucleoside diphosphokinase in rat tissues. Biochemistry (1973) 0.82
Inhibition of the growth of human colon cancer xenografts by polar solvents. Cancer Res (1982) 0.82
Effect of chirality in erythro-9-(2-hydroxy-3-nonyl) adenine (EHNA) on adenosine deaminase inhibition. Biochem Pharmacol (1982) 0.82
Plasma adenosine deaminase2: a marker for human immunodeficiency virus infection. J Acquir Immune Defic Syndr (1991) 0.82
Role of adenosine uptake and metabolism by blood cells in the antiplatelet actions of dipyridamole, dilazep and nitrobenzylthioinosine. Biochem Pharmacol (1985) 0.81
Pathways of nucleotide metabolism in Schistosoma mansoni. IV. Incorporation of adenosine analogs in vitro. Biochem Pharmacol (1973) 0.81
N-Methylformycins. Reactivity with adenosine deaminase, incorporation into intracellular nucleotides of human erythrocytes and L 1210 cells and cytotoxicity to L 1210 cells. Biochem Pharmacol (1979) 0.81
Adenosine analogs and human platelets--II. Inhibition of ADP-induced aggregation by carbocyclic adenosine and imidazole-ring modified analogs. Significance of alterations in the nucleotide pools. Biochem Pharmacol (1979) 0.81